Your session is about to expire
← Back to Search
Alpha-1 Adrenergic Receptor Antagonist
Terazosin for Healthy Subjects
Phase 1
Waitlist Available
Led By Jordan Schultz, PharmD
Research Sponsored by University of Iowa
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Healthy Men or women aged 60-90
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up ongoing (days 1 - 37)
Awards & highlights
Study Summary
This trial will help researchers understand if Terazosin helps to reduce symptoms related to certain medical conditions.
Who is the study for?
This trial is for healthy men and women aged between 60-90 years old. The details about what might exclude someone from participating are not provided, but typically would involve factors that could affect the safety of participants or the results of the study.Check my eligibility
What is being tested?
The study is testing Terazosin (TZ) in a small group of 6 healthy adults to see how well it engages with its target in the body. Participants will undergo advanced imaging tests like PET/CT scans and high-field MRI, along with blood tests, and may choose to have a spinal tap procedure.See study design
What are the potential side effects?
Since this trial involves healthy subjects, side effects might include reactions at injection sites, discomfort from imaging procedures or blood draws, headache or back pain after lumbar puncture if chosen.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ ongoing (days 1 - 37)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~ongoing (days 1 - 37)
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in ATP in the blood from baseline to 1 week (1mg of terazosin)
Change in ATP in the blood from baseline to 5 week (1mg of terazosin)
Change in ATP in the brain from baseline to 1 week (1mg of terazosin)
+7 moreSecondary outcome measures
Safety and Tolerability
Trial Design
1Treatment groups
Experimental Treatment
Group I: Primary CohortExperimental Treatment1 Intervention
Titrating doses of terazosin starting at 1mg daily and increasing to 5mg daily on a weekly basis for five weeks.
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
University of IowaLead Sponsor
446 Previous Clinical Trials
879,484 Total Patients Enrolled
Michael J. Fox Foundation for Parkinson's ResearchOTHER
112 Previous Clinical Trials
535,138 Total Patients Enrolled
Jordan Schultz, PharmDPrincipal Investigator - University of Iowa
University of Iowa
1 Previous Clinical Trials
13 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger